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Clinical Implications
• There had been a substantial increase in the use of ADs among children and adolescents. The number of prescriptions per patient increased.
• Family physicians played a major role in the use of ADs, but their role decreased after 2004.
• Continued emphasis on training and education in the use of pediatric ADs is warranted.
Limitations
• Data used was multiple cross-sectional.
• The analysis of variables related to AD prescription is restricted, due to the existing variable limitation in the data source.
• Data analyzed was for the Saskatchewan population, and may not be generalizable to other provinces in Canada.
S
ince researchers in the 1950s discovered the first ADs, TCAs, and MAOIs, a wide variety of ADs have become available and commonly prescribed to children and adolescents for depression, anxiety, and other mental disorders. 1 The diversity of ADs allows clinicians to individualize treatment decisions for psychiatric symptoms, as well as to avoid potential side effects. 2 Increased use of ADs for youth has been reported over decades in the United Kingdom, Italy, Denmark, the Netherlands, and the United States. [3] [4] [5] SSRIs have been the major contributor to this upward trend. 3, 6 Like all medications, ADs warrant concerns in terms of efficacy, tolerability, and safety. 7 Generally, ADs have several side effects, such as weight gain, sexual dysfunction, fatigue, and sleepiness. Consequences of these side effects may adversely impact patients' compliance and thereby influence outcome, and increase risk of morbidity and mortality. 7 There have been further concerns expressed about the safety issue of ADs in pediatric patients. [8] [9] [10] In 2004, drug regulatory agencies in the United States (Food and Drug Administration), Canada (Health Canada), and the United Kingdom (Medicines and Healthcare Regulatory Agency) released warnings on ADs in pediatric patients, including suicidality, violence, aggression, mania, and other abnormal behavioural changes. 11 Epidemiologic studies on trends of AD use in children and adolescents have been conducted to examine the influence of warnings on the use of ADs. Generally, prescriptions of SSRIs (except fluoxetine, which remained stable) decreased during 2003 to 2005, but increased afterwards. 6, [12] [13] [14] Notably, there has been significant national variability in patterns of psychotropics practice, owing to the introduction of new drugs, controversies over which drugs are better and more effective, different drug regulations, drug safety, cultural meaning of drug treatment in pediatric populations, and each country imprinting its own particular culture. 15, 16 Recently, Tsapakis et al 17 conducted a systematic review and meta-analysis of randomized controlled trials comparing responses to ADs and placebo in youth with depression. They concluded that most ADs, with the exception of fluoxetine, provided only limited efficacy in adolescent depression. Although clinical trials generally could provide better quality evidence than other study designs, short-term follow-up and small sample size limit the use of clinical trials in exploring trends of using pharmaceuticals. Health policy experts have suggested that existing health record databases should be studied to identify early warnings of adverse side effects of drugs, and to develop evidencebased health policy. 18 Given the widespread use of ADs, the possibility of suicidality induced by ADs among children and adolescents, and different patterns of medication practice, data on the long-term trend of pediatric AD use in a general population are needed. In our study, we aimed to examine trends in pediatric AD use in general and in population subgroups over a 24-year period in a Canadian provincial population.
Methods
Context
Provincial governments in Canada take the responsibility of most health services delivered within their provinces. Although the precise range of services may vary by province, these services include almost all hospital and physician services, as well as a significant proportion of nursing home care, prescription drug subsidies, and public health. 19 Saskatchewan is a prairie province, which has a 20 The Saskatchewan population of children and adolescents (excluding registered First Nations) decreased from 309 385 in 1983 to 248 645 in 2007. There were consistently more males than females during the 24-year period. The proportions of younger age groups among children and adolescents decreased, whereas the proportion of older adolescents increased during the study period (online eAppendix 1).
Data Source
The data used were from the outpatient prescription drug data files of the Saskatchewan Ministry of Health. The detailed AD dispensing information for patients had been recorded in the drug file. The data released to researchers by the provincial Ministry of Health are subject to restraints and dummy identification to ensure confidentiality. These are anonymous administrative data; therefore, no ethics board approval is required for this type of study. The data include information for all beneficiaries eligible for prescription drug benefits. All Saskatchewan residents are eligible for prescription drug benefits except those who receive these benefits from the federal government (for example, veterans for service-related illnesses and registered Indians, about 10% of the provincial population). This constitutes covered population. The cross-sectional data were organized for 9 triennial years from 1983 to 2007. Data analyzed here are population-based.
Measures
For our study, the detailed information on 22 ADs, categorized into subclasses, prescribed by physicians, and dispensed by a community pharmacy, was extracted from the prescription drug database. The data documented individual prescriptions during a calendar year and included information on sex, age, AD drug category, and prescriber specialty. The 4 subclasses of ADs analyzed were SSRIs, MAOIs, TCAs, and other ADs (details on the drugs covered are shown in online eAppendix 2).
Data Analysis
Descriptive statistics were used to estimate rates of pediatric AD use in general and for subgroups. The age distribution of the total 9 years covered youth population was used as a standardization reference. The age-specific dispensing rates for each individual year were then calculated. The agestandardized dispensing rates for all study years were then computed, based on the age distribution of the standardized population and age-specific dispensing rates. Data analysis was conducted using IBM SPSS Statistics, version 19.0 (IBM Corp, Armonk, NY).
Results
There were 1814 children and adolescents in Saskatchewan (5.9 per 1000 population of the covered children and adolescents aged 0 to 19) Evidence shows that mental disorders, especially depression, are being more frequently diagnosed among children and adolescents. Epidemiologic studies have found that mood and anxiety disorders are the most common psychiatric disorders in children and adolescents, and are likely to be chronic and increase vulnerability to other diseases. 21, 22 A population-based study on children and adolescents had shown that those who were growing up in the 1990s had a 1 in 6 chance of getting a psychiatric disorder and the rate increased to 1 in 3 by the age of 16. 23 Costello et al 24 systematically conducted a meta-analytic study on the prevalence of depression between 1965 and 1996, and found that the prevalence of depression was 2.8% for those aged under 13, 5.9% for girls aged between 13 to 18, and 4.6% for boys aged 13 to 18. O'Neil et al 25 in their review suggest that community and clinical studies have shown that a range of 9.0% to 47.9% of adolescents had comorbidity between internalizing disorders and substance use. Recently, Merikangas et al 26 reviewed the magnitude of mental disorders in children and adolescents; despite The safety issue of ADs in children and adolescents has been studied, but the efficacy of these drugs in juvenile depression has not been explicitly studied. More importantly, although CBT has been widely seen as an evidence-based treatment in children and adolescents, and has been considered as the most appropriate treatment for those who suffer from mild mental disorders, 27 pharmacotherapy, and in particular ADs, may be an alternative or adjunct to CBT for more severe cases. 28 Consistent with studies conducted in Quebec, 29 Taiwan,   30 the United States, 31 the trend of AD use in children and adolescents has increased since the late 1990s. This trend was mainly a result of the increased use of SSRIs and other ADs. Our study found that the rate of pediatric use of ADs in Saskatchewan was 5.9 per 1000 in 1983, decreased in 1989, and then increased to 15.4 per 1000 in 2007. Pediatric AD use of children and adolescents in Taiwan increased during 1997 to 2005 from 2.7 per 1000 to 4.7 per 1000. 30 The US rates increased from 13 per 1000 in 1997 to 18 per 1000 in 2002. 31 Caution has to be paid when comparing the rate of pediatric AD use among studies for 3 reasons: studies were conducted at different time periods; characteristics of subjects varied by study; and insurance coverage of ADs differed.
Regulatory warnings resulted in a temporal decline in pediatric AD use during 2003 to 2005, but the use of ADs rebounded afterwards. 10, 32, 33 This phenomenon could be explained by the following: clinicians were influenced by regulatory warnings in terms of making psychiatric diagnosis and offering prescriptions, and further studies on safety issues of ADs did not find evidence to support suicidal and violent acts as induced by ADs in youth, 34 the influence of those warnings on clinicians was short-term. Our study found that a slower increase of pediatric AD use after 2004, which is in line with the trends in SSRI use in pediatric patients reported by a Quebec study 29 and a Taiwanese study, 30 and a decrease in the rate of ADs dispensed by family physicians after 2004, which may indicate that they were influenced by the warnings.
Our study also observed the prevalence of pediatric AD use increased with age. The increasing trend in use from 1983 to 2007 was most pronounced in the adolescent group (aged 15 to 19), and their use getting more frequent; this is also true for other studies. 3, 4, 8, 35 Adolescents are more likely to be judged to suffer with depression, anxiety, and other psychological difficulties, compared with children. The substantial increasing use of SSRIs is consistent with an increasing number of adolescent psychiatric patients. 36 Females were more likely to use ADs in our study. Inconsistent findings on the role of sex in pediatric AD use have been reported. 29, 30 The discrepancy may be explained by the prevalence of psychiatric disorders varying between the sexes at different ages, and by structural differences in the proportions of males and females at different ages across studies.
Notably, the use of TCAs remained fairly constant over the study period. There was a dramatically decreasing trend in the usage of TCAs for those aged younger than 9 years. Conversely, adolescents aged 15 to 19 were dispensed an increasing number of TCAs. In addition, our study found that TCA use was more frequent in adolescents. It was likely that TCAs were used to treat psychiatric problems in this age group. Though one might consider TCAs prescribed for physical problems, such as bedwetting, we found a dramatically decreasing trend in the usage of TCAs for those aged younger than 9 years.
Family physicians played the major role in AD prescribing, followed by psychiatrists. However, there was a decrease in the prescription rate of ADs by family physicians after 2004. This phenomenon may be explained by the following: family physicians may be more influenced by the regulatory warnings; or the prescribing of ADs in children and adolescents shifted from generalists to psychiatric specialists, 37 as we observed the rate of ADs dispensed by psychiatrists consistently increased during the 24-year period. The number of AD prescriptions dispensed per patient also increased, which parallels findings from the United States. 38 Several findings from our comparison of AD use across subgroups warrant further attention. First, the effectiveness and appropriateness of frequently used ADs should be examined. Second, family physicians played a major role in AD prescriptions; therefore, continuing training and education on their use of ADs should be reinforced. Third, given the dramatic increase of SSRI use, research should be strengthened on the effectiveness and safety of individual SSRIs, and should help to identify the relative safety and balance of risks for pediatric patients.
Our study has some limitations. First, the range of variables in the data analyzed limits our ability to explore roles of other variables that may influence use. Second, data only had categorical information on the subclasses of ADs, data on specific ADs were not retrieved. Third, since our study only had one study point after 2004, the trend of pediatric AD use after regulatory warning needs to be reexamined with further post-2004 data.
Conclusions
Saskatchewan experienced an increasing trend in pediatric AD use from 1983 to 2007. The use of SSRIs significantly contributed to the trend. Family physicians and psychiatrists were the major prescribers. AD use increased with age, and the number of prescriptions per patient became more frequent. Given the use of ADs had dramatically increased, the possibility of safety issues induced by AD use among children and adolescents, and different patterns of medication practice, continuing education is warranted.
